Stay updated with breaking news from Lon Val. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ValiRx plc (LON:VAL – Get Rating)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 13.50 ($0.17) and traded as low as GBX 8.90 ($0.11). ValiRx shares last traded at GBX 8.90 ($0.11), with a volume of 272,782 shares traded. ValiRx Stock […]
ValiRx plc (LON:VAL – Get Rating)’s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 12.23 ($0.15) and traded as high as GBX 18.85 ($0.23). ValiRx shares last traded at GBX 17.25 ($0.21), with a volume of 1,989,192 shares changing […]
Shares of ValiRx plc (LON:VAL – Get Rating) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 27.16 ($0.36) and traded as high as GBX 31.60 ($0.41). ValiRx shares last traded at GBX 29.50 ($0.39), with a volume of 407,786 shares. The […]
ValiRx plc (LON:VAL – Get Rating)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 26.96 ($0.35) and traded as low as GBX 26.75 ($0.35). ValiRx shares last traded at GBX 26.75 ($0.35), with a volume of 582,447 shares trading […]
27 April 2021 | 08:46am StockMarketWire.com - Clinical-stage drug development company ValiRx narrowed full-year losses after it cut back on R&D and administrative spending. Pre-tax losses for the year through December amounted to £1.54 million, compared to year-on-year losses of £2.7 million. The company said it had launched a new strategy and implemented structural changes to develop 'a risk-diversified approach to early-stage drug development'. A phase 1/2 clinical trial close out and reporting of lead asset VAL201 had demonstrated good safety and tolerability and early indications of eff...